Is Quest Diagnostics (DGX) overvalued or fairly valued?

MarketChacha shows Quest Diagnostics's valuation in context — a forward P/E of about 17.8, a price-to-book of about 3.1 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is the share price of Quest Diagnostics (DGX)?

Quest Diagnostics last traded at $207.40 (+0.3% on the day), as of 7/22/2026 — a delayed quote shown for education, not investment advice.

Quest Diagnostics

DGX · NYSE · Healthcare · United States

$207.40+0.3%

Delayed · as reported by Yahoo Finance · as of Jul 22, 2026, 5:38 PM

Snapshot

TickerDGX

ExchangeNYSE

SectorHealthcare

IndustryDiagnostics & Research

CountryUnited States

Employees57,000

HeadquartersSecaucus, United States

Market cap$23.0B

P/B3.1

Volume351.66K

Websitewww.questdiagnostics.com

Filings tracked0

About Quest Diagnostics

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It also provides services under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers commercial clinical laboratories, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. In addition, the company offers risk assessment services for the life insurance industry; healthcare IT healthcare providers and payers; testing and medical director services at hospital laboratories; test offerings in cardiometabolic and endocrine; cancer; clinical drug monitoring and toxicology; infectious disease, including autoimmune; neurology diagnostics, including Alzheimer's disease; and women's health, such as prenatal genetic; workplace drug testing, testing urine, hair, and oral fluid specimens services; and employer population health services, including biometric screenings, flu shots, and related preventative services. Further, it provides population health solutions; extended care services; develops in vitro diagnostic tests; laboratory diagnostic information and digital health connectivity systems; underwriting support services, including data gathering, paramedical examinations, and clinical laboratory testing and analytics; and national specimen collection and health data solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.

Profile as reported by Yahoo Finance.

Who owns it

Insiders0.4%
Institutions98.1%
Public & other1.5%

1,481 institutional holders

As reported by Yahoo Finance.

Top holders

Blackrock Inc.8.29%
Vanguard Capital Management LLC6.46%
Price (T.Rowe) Associates Inc5.69%
Vanguard Portfolio Management LLC5.49%
State Street Corporation4.86%
Boston Partners3.62%
JPMORGAN CHASE & CO3.47%
Geode Capital Management, LLC2.79%

Largest institutional holders, as reported by Yahoo Finance (as of 3/31/2026).

What's expected next

Next quarter

Rev $3.0B · EPS 2.80

Est. earnings growth +7.8%

Next fiscal year

Rev $12.4B · EPS 11.67

Est. earnings growth +8.4%

Analyst consensus estimates — not the company's own guidance. As reported by Yahoo Finance.

$165.7852-wk range$219.20

Delayed · as reported by Yahoo Finance

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Ask MarketChacha about DGX

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed · as reported by yahoo finance) are delayed and shown for reference only. Verify with the linked sources before acting.